The multicenter study to examine angiogenesis-related factors in advanced colorectal cancer

Conditions

Colorectal cancer

Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando et al. (21 authors)

Clinical Colorectal Cancer2024-01-181 citations

10.1016/j.clcc.2024.01.003

Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in <i>RAS</i> wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.

Satoshi Yuki, Yu Sunakawa, Kentaro Yamazaki, Hiromichi Shirasu, Hiroya Taniguchi et al. (20 authors)

Journal of Clinical Oncology2022-06-01

10.1200/jco.2022.40.16_suppl.3530

Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study.

Yu Sunakawa, Satoshi Yuki, Manabu Shiozawa, Toshiki Masuishi, Tomohiro Nishina et al. (20 authors)

Journal of Clinical Oncology2021-05-202 citations

10.1200/jco.2021.39.15_suppl.3529

Plasma VEGF-D and PlGF levels according to prior use of biologics among metastatic colorectal cancer: Preliminary results from GI-SCREEN CRC-Ukit study.

Hiroya Taniguchi, Satoshi Yuki, Manabu Shiozawa, Toshiki Masuishi, Tomohiro Nishina et al. (20 authors)

Journal of Clinical Oncology2020-02-016 citations

10.1200/jco.2020.38.4_suppl.178

The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.

Satoshi Yuki, Kentaro Yamazaki, Hiroya Taniguchi, Yu Sunakawa, Akihito Kawazoe et al. (20 authors)

Journal of Clinical Oncology2018-02-011 citations

10.1200/jco.2018.36.4_suppl.tps885

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with pathologically or histologically confirmed colorectal cancer 2)Patient with indication of chemotherapy with unresectable metastasis or recurrent disease 3)Confirmed RAS mutational status 4)Meet the following (1) or (2) (1)Patients who have not administerd chemotherapy for metastatic disease (2)Patients immediately after completion of chemotherapy plus bevacizumab or chemothrapy plus anti-EGFR antibody for the first line treatment for metastatic disease 5)Patient who is planned to receive following (1) to (5) after registration (1)chemotherapy plus bevacizumab (first line) (2)chemotherapy plus anti-EGFR antibody (first line) (3)FOLFIRI plus ramucirumab (second line) (4)FOLFIRI plus aflibercept (second line) (5)chemotherapy plus bevacizumab (second line) 6)Age 20 years or above 7)Written informed consent was obtained

Exclusion criteria

Exclusion criteria: 1)Judged by the investigator to be inappropriate for study participation for any reason

Design outcomes

Primary

Measure	Time frame
Relationship between angiogenesis-related factors and therapeutic effects in advanced colorectal cancer	—

Secondary

Measure	Time frame
Association between pre-treatment angiogenesis-related factors and clinicopathological features Fluctuant of factors angiogenesis-related factors pre- and post chemotherapy	—

Countries

Japan

Contacts

Public ContactSatoshi Yuki

Hokkaido University Hospital Department of Gastroenterology and Hepatology

satoshi-yuuki175@joy.ocn.ne.jp011-706-5657

Outcome results